Musi wa1 Chivabvu 2025, Hansoh Pharmaceutical yakazivisa kuti mushonga weB7-H4-targeted antibody-drug conjugate (ADC) HS-20089 weBoka wakazvigadzira wega wekubaiwa jekiseni wawana mvumo yekuverengerwa semushonga weBreakthrough-Therapy-Designated neNational Medical Products Administration (NMPA) yeChina, nechiratidzo chakakurudzirwa chevarwere vane kenza ye ovarian isingapindike neplatinum, kenza ye fallopian tube kana varwere vane kenza ye peritoneal primary.
Kusarudzwa uku kunotsigirwa nemhedzisiro yechidzidzo chePhase I HS-20089-101 uye chidzidzo chePhase II HS-20089-201. Chidzidzo cheHS-20089-101 iongororo yekiriniki yePhase I ine nzvimbo dzakawanda, yakavhurika yekuongorora kuchengetedzeka, kushivirira, pharmacokinetics, uye kushanda kweHS-20089 yekubaiwa jekiseni muvarwere vane bundu rakasimba. Chidzidzo cheHS-20089-201 iongororo yekiriniki yePhase II ine nzvimbo dzakawanda, yakavhurika yekuongorora kushanda, kuchengetedzeka, chimiro chemishonga, uye immune system yeHS-20089 muvarwere vane kenza ye ovarian inodzoka kana yakapararira uye kenza ye endometrial.
HS-20089 iADC inotarirwa neB7-H4 ine topoisomerase inhibitor (TOPOi) payload iri kugadzirwa kurapa kenza yemazamu nemamwe mabundu evakadzi mukuyedzwa kwakawanda kwekiriniki muChina, nedanho repamusoro rekutsvagisa riri Phase III clinical trials. B7-H4 itransmembrane immune checkpoint glycoprotein inoratidzwa zvakanyanya mumabundu akawanda akasimba, kusanganisira kenza ye endometrial nekenza yemazamu, asi isina kuratidzwa kwakakwana mumatishu akajairwa.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Imeyili：myimmnet@163.com
Nguva yekutumira: Chivabvu-09-2025